Investigational drug · Phase 2
TG4001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "TG4001"
First trial start
2017
Sep 1, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TG4001", any sponsor or status.
Conditions studied
As listed on its trial records.
- HPV-Related Carcinoma
- HPV-Related Cervical Carcinoma
- HPV-Related Anal Squamous Cell Carcinoma
- HPV-Related Penile Squamous Cell Carcinoma
- HPV-Related Vulvar Squamous Cell Carcinoma
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "TG4001" as an intervention, largest first.
- Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M CancersPivotal-lookingActive, not recruiting
TransgeneIndustry
NCT03260023 · 143 participants · Start Sep 1, 2017 · Primary completion Sep 18, 2024
Drug: TG4001; Avelumab · For: HPV-Related Carcinoma; HPV-Related Cervical Carcinoma; HPV-Related Anal Squamous Cell Carcinoma and 2 more
Sites: Jacksonville, Florida; Rochester, Minnesota; Angers, France · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Advances in Therapeutic Vaccines Against HPV: A Review of Human Clinical Trials.
Martín E, Reina G, Carlos S · Curr Oncol 2025
- Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers.
Borcoman E, Lalanne A, Delord JP, et al. · Eur J Cancer 2023
- Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy.
Brun JL, Dalstein V, Leveque J, et al. · Am J Obstet Gynecol 2011
Also in development for HPV-Related Carcinoma
- PRGN-2009Phase 21 trial
Precigen, Inc · Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.